Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cook Islands Tech Reporter.
Press releases published on July 24, 2025
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation …
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has …
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
Boca Raton, July 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be released in an oral presentation at the …
DebitMyData Closes Oversubscribed Seed Round- Launches $1B Human Energy Grid Global Expansion
DebitMyData™ Logo FORT LAUDERDALE, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- DebitMyData™, Inc.—the powerhouse has closed a seed round at more than twice its original target. This surge of investor confidence paves the way for a bold, billion-dollar global …
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
LA JOLLA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides an …
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on …
Nano Labs Appoints Ms. Can Yang as Senior Vice President of Subsidiary Nano bit to Oversee Execution of Digital Currency Strategic Reserves and Strengthen BNB Reserve Capabilities
HONG KONG, July 24, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider in China, today announced the appointment of Ms. Can Yang as senior vice president …
CLEAR, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening a New Location at Aventura Mall in South Florida
NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), an authorized TSA PreCheck® enrollment provider, continues to expand locations outside the airport environment to enroll and renew consumers in the Trusted Traveler program by opening a new …
SALTGATOR Debuts Desktop Soft-Gel Injection Machine on Kickstarter — A Game-Changer for Makers
DICKINSON, Texas, July 24, 2025 (GLOBE NEWSWIRE) -- SALTGATOR Tech Inc., an Dickinson-based startup dedicated to accessible fabrication tools, is proud to announce the launch of its Kickstarter campaign for the SALTGATOR — the world’s first desktop soft- …
Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients
Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex …
Aurora Mobile CEO Comments on Robinhood CEO's Crypto Remarks
SHENZHEN, China, July 24, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today issued a statement from its CEO, Mr. Luo …
Rhombus Expands AI-Powered Operational Analytics by Launching Line Crossing and Occupancy Counting
SACRAMENTO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Rhombus, a leader in cloud-managed physical security solutions, today announced the expansion of its AI-powered Operational Analytics capabilities with two powerful new features: Line Crossing and …
First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
Group net sales grow by 6.3%* to EUR 14.0 billion, driven by Human Pharma (EUR 11.3 billion) and Animal Health (EUR 2.6 billion) Regulatory submissions underway for zongertinib and nerandomilast, with launches expected in H2 2025 Strategic investments in …
Citryll Announces Formation of Scientific Advisory Board
CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD Board comprises world-renowned experts in biology, immunology and pathology Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune- …
AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA
COMMUNIQUÉ DE PRESSE AB SCIENCE A OBTENU L'AUTORISATION DE PLUSIEURS PAYS EUROPÉENS POUR INITIER L’ETUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE CETTE AUTORISATION FAIT SUITE A LA VALIDATION DU PROTOCOLE PAR L’EMA …
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL VALIDATION BY THE EMA AND FDA AUTHORIZATION Paris, July …
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused …